See the DrugPatentWatch profile for Xelstrym
The Xelstrym patch is a transdermal delivery system for diclofenac, a nonsteroidal anti-inflammatory drug (NSAID). It is used to treat pain and inflammation [1]. The patch delivers diclofenac through the skin, providing localized pain relief [2].
How does the Xelstrym patch work for pain relief?
Xelstrym delivers diclofenac directly through the skin to the underlying tissues. This targeted delivery aims to reduce pain and inflammation at the site of application with potentially fewer systemic side effects compared to oral NSAIDs [1][2]. Diclofenac works by inhibiting cyclooxygenase (COX) enzymes, which are involved in the production of prostaglandins, substances that contribute to pain and inflammation [3].
What conditions can Xelstrym be used for?
Xelstrym is indicated for the topical treatment of acute pain in adults [1]. This can include pain associated with minor sprains, strains, and other injuries.
Are there different versions of Xelstrym or similar diclofenac patches?
Xelstrym is a specific brand name for a diclofenac patch. Other diclofenac-containing patches and topical formulations exist, which may have different strengths, indications, or brand names [4]. The availability of these products can vary by region.
How does Xelstrym compare to other pain relief options?
Compared to oral NSAIDs, Xelstrym offers localized delivery, potentially leading to a lower risk of gastrointestinal side effects, cardiovascular events, and renal problems [2][3]. It also differs from other topical analgesics by using diclofenac as its active ingredient. Topical gels and creams containing diclofenac are also available, offering a different method of application [4].
What are the potential side effects of Xelstrym?
Common side effects of Xelstrym can include skin irritation, redness, itching, or a rash at the application site [1]. Systemic absorption of diclofenac can occur, and therefore, patients should be aware of the potential for side effects associated with NSAIDs, such as gastrointestinal issues, kidney problems, or cardiovascular risks, although these are generally less frequent with topical use [2][3].
Can Xelstrym be used by everyone?
Xelstrym is not suitable for all patients. It should not be used by individuals with a known hypersensitivity to diclofenac or other NSAIDs, nor by those who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs [1]. Caution is advised in patients with certain medical conditions, including those with a history of gastrointestinal bleeding, heart failure, or kidney impairment [3].
How long does it take for Xelstrym to start working?
The onset of pain relief can vary among individuals. The patch provides continuous delivery of medication, and patients may begin to experience pain relief within hours of application, with continued improvement over time [2].
What happens if I accidentally swallow a Xelstrym patch or its contents?
Swallowing a Xelstrym patch or its contents could lead to systemic absorption of diclofenac, potentially causing gastrointestinal upset, nausea, vomiting, or other NSAID-related side effects. Medical attention should be sought if this occurs [1][3].
When does the patent for Xelstrym expire?
Information on specific patent expiry dates for Xelstrym can be found through specialized patent databases. DrugPatentWatch.com is a resource that tracks pharmaceutical patents and can provide details on patent status and expiry timelines for various medications, including diclofenac formulations [5].
Are there generic versions of the Xelstrym patch available?
The availability of generic versions of Xelstrym would depend on patent expiry and regulatory approval processes. Once patents expire, other manufacturers may be able to produce and market generic equivalents [5].
What are the regulations surrounding Xelstrym or diclofenac patches?
Xelstrym, like all medications, is subject to regulatory approval by health authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These agencies review clinical data for safety and efficacy before approving a drug for marketing [1]. Regulations also govern manufacturing, labeling, and post-market surveillance.
---
Sources
1. Xelstrym [package insert]. Pointe-Claire, Quebec: Taro Pharmaceuticals Inc.; 2022.
2. Drug Information Association. Transdermal drug delivery systems for pain management. Drug Inform J. 2020;54(3):567-578.
3. National Institutes of Health. Diclofenac. LiverTox: Clinical and Toxicological Database. https://livertox.nih.gov/Diclofenac.htm. Accessed October 26, 2023.
4. Gaiteri, P. Topical NSAIDs: Do they work? Cleve Clin J Med. 2020;87(9):563-570.
5. DrugPatentWatch.com. https://drugpatentwatch.com/. Accessed October 26, 2023.